Navigation Links
Discovery Labs Prices $50 Million Public Offering of Common Stock
Date:10/31/2013

WARRINGTON, Pa., Oct. 31, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that it has priced an underwritten public offering of 25 million shares of its common stock, at a price to the public of $2.00 per share for gross proceeds of $50 million.  Net proceeds, after underwriting discount and other estimated fees and expenses payable by the Company, are expected to be approximately $47 million.  The offering is expected to close on or about November 5, 2013, subject to satisfaction of customary closing conditions.  In addition, the underwriters have been granted a 30-day option to purchase up to an additional 3.75 million shares of common stock to cover over-allotments, if any.  Stifel and Piper Jaffray & Co. are acting as joint bookrunning managers for the offering, Lazard Capital Markets LLC is acting as co-lead manager and Roth Capital Partners, LLC is acting as co-manager.

The securities described above are being offered by Discovery Laboratories, Inc. pursuant to a shelf registration statement on Form S-3, together with a base prospectus, previously filed and declared effective by the Securities and Exchange Commission (SEC).  The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.  A preliminary prospectus supplement related to the offering was filed with the SEC on October 30, 2013.  When available, copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the Securities and Exchange Commission web site at http://www.sec.gov, or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, S
'/>"/>

SOURCE Discovery Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Discovery Labs Announces Proposed Public Offering of Common Stock
2. Productivity Crisis in Pharmaceutical Industry Increases Drug Prices; The CBCD Offers New Technology to Aid in Drug Discovery
3. Vet-Stem, Inc. Founder and CEO Presents at TargetMeeting’s 3rd World Drug Discovery Online Conference
4. Drug Discovery Using Natural Products - Optimization Studies of Inhibitors of Glucan Synthesis as Anti-Fungal Agents, New Life Science Webinar Hosted by Xtalks
5. Global Biosimulation Technology Market (For Drug Discovery & Development) (2012 - 2017)
6. Discovery Meets Recovery in New Cedars-Sinai’s Advanced Health Sciences Pavilion Designed by HOK
7. Discovery Channel MythBuster Star Jaime Vendera First Person on Record to Break a Glass with His Voice Endorses UV-Aid by UV Technologies, LLC
8. Meso Scale Discovery Launches V-PLEX™ Multiplex Biomarker Immunoassays
9. Accidental nanoparticle discovery could hail revolution in manufacturing
10. Discovery Labs to Present at Stifel Healthcare Conference 2013
11. Sigma Life Science Licenses CompoZr Zinc Finger Nuclease Technology to Horizon Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... YARDLEY , Pennsylvanie, 18 septembre 2014 ... Lyon en 1974, a été ... à compléter les évaluations cliniques traditionnelles par ... Reported Outcomes) et sur les impacts économiques ... http://photos.prnewswire.com/prnh/20140618/119365 A cours ...
(Date:9/18/2014)... OMICS Group International invites researchers, authors and academicians ... Access Week’ by actively contributing their research outcome ... from 20-26th October, 2014. , Pharmaceutical Sciences ... with a tremendous speed to provide improved medical ... is gearing with innovation and technological revolution to ...
(Date:9/18/2014)... a group of rare diseases that afflict skeletal ... onset hits at the fetal stage and is ... gene encoding fibroblast growth factor receptor 3 (FGFR3) ... dysplasia, thanatophoric dysplasia (TD), a skeletal dysplasia that ... often lethal, and achondroplasia (ACH), which causes stunted ...
(Date:9/18/2014)... Artificial sweeteners, promoted as aids to weight loss and ... intolerance and metabolic disease; and they do it in ... of the gut microbiota the substantial population of ... of experiments in mice and humans, were published today ... Eran Elinav of the Weizmann Institute,s Immunology Department, who ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3
... until further notice, RICHMOND, Va., Oct. 21 Insmed ... that on Thursday, October 16, 2008 NASDAQ issued a notice ... the enforcement of the rules ... Effective immediately, NASDAQ has also suspended the enforcement of the ...
... SAN DIEGO, Oct. 21 Althea Technologies, ... technologies for pharmaceutical,development and manufacturing, announced today ... as its President and Chief Executive Officer. ... Services (PDS) at,Patheon, Inc., will lead Althea,s ...
... Calif., Oct. 21 (11:00 PM PT,Oct. 20) ... announced that,Novartis AG has agreed to acquire from ... for $115 million in cash., "This agreement ... the development,of novel therapeutics using our PEGylation and ...
Cached Biology Technology:Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule 2Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule 3Althea Technologies Appoints Dr. Shabbir Anik as Chief Executive Officer 2Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder 2Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder 3Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder 4
(Date:9/18/2014)... matter how many times it,s demonstrated, it,s still ... , But by using a signaling system ... their behavior to suit their population. In short, ... present, and act accordingly. , Once the population ... change from innocuous to pathogenic, or from unhelpful ...
(Date:9/18/2014)... Sept. 18, 2014 -- Arizona turned its newborn screening program ... few short months, earning it the first-ever Newborn Screening Quality ... of Dimes presented Will Humble, M.P.H., Arizona,s Department of Health ... today. Mr. Humble established a policy of full transparency for ... newborn blood samples to the lab for analysis, and set ...
(Date:9/18/2014)... global cycles of carbon and nitrogen comprise all ... and environmental systems have caused imbalances and perturbations ... gases (GHGs). Increased GHGs result in climate changes ... ecosystems, oceans and the atmosphere. Understanding these feedback ... branch of environmental science during the past three ...
Breaking Biology News(10 mins):Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Greenhouse gas research enters a new era 2
... NJIT Distinguished Professor Philip R. Goode and the Big Bear ... a deformable mirror in what is called adaptive optics ... an image of a sunspot was published yesterday on the ... day: http://www.cieletespace.fr/node/5752 "This photo ...
... With children going back to school, parents are concerned that ... who dine in a school cafeteria. New research funded ... eat school lunches that are part of the federal government,s ... The same research study found, however, that children who ...
... to locate and identify a gene responsible for a fatal ... may be responsible for a similar rare, fatal disease in ... of the disease in dogs and is the first step ... Dr. Natasha Olby, associate professor of neurology, was part ...
Cached Biology News:See amazing new sun images from NJIT's Big Bear Solar Observatory 2USDA-backed study finds federal school lunches linked to childhood obesity 2USDA-backed study finds federal school lunches linked to childhood obesity 3Researchers find gene responsible for neurodegenerative disease in dogs, possibly in humans 2
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Rabbit polyclonal to Testosterone 19 ( Abpromise for all tested applications). Antigen: Testosterone 19 CME HSA (Human)...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Biology Products: